Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: A prospective multicenter clinical trial

Journal of Urology

Volumn 162, Issue 4, 1999, Pages 1346-1351

  Southwick, Paula C ^a   Catalona, William J ^a,b   Partin, Alan W ^a   Slawin, Kevin M ^a   Brawer, Michael K ^a   Flanigan, Robert C ^a   Patel, Anup ^a   Richie, Jerome P ^a   Walsh, Patrick C ^a   Scardino, Peter T ^a   Lange, Paul H ^a   Gasior, Gail H ^a   Parson, Robert E ^a   Loveland, Kathleen G ^a  

^a Hybritech Incorporated   (United States)

^b Division of Urologic Surgery   (United States)

Author keywords

Neoplasm staging; Prostate, prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

EID: 0032869327     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68282-1     Document Type: Article

References (33)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer Statistics, 1998. CA Cancer J. Clin., 48: 6, 1998.
2. Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., Waters, W. B., MacFarlane, M. T. and Southwick P. C.: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men. J. Urol., 151: 1283, 1994.
3. Partin, A. W., Kattan, M. W., Subong, E. N. P., Walsh, P. C., Wojno, K. J., Oesterling, J. E., Scardino, P. T. and Pearson, J. D.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J.A.M.A., 277: 1445, 1997.
4. Christensson, A., Laurell, C. B. and Lilja, H.: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755, 1990.
5. Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K. and Lövgren, T.: Prostate-specific antigen in human serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem., 37: 1618, 1991.
6. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer. Res., 51: 222, 1991.
7. Christensson, A., Bjork, T., Nilsson, O., Dahlén, U., Matikainen, M. T., Cockett, A. T. K., Abrahamsson, P.-A. and Lilja, H.: Serum prostate specific antigen complexed to alpha-1-antichymotrypsin as an indicator of prostate cancer. J. Urol., 150: 100, 1993.
8. Catalona, W. J., Smith, D. S., Wolfert, R. L., Wang, T. J., Rittenhouse, H. G., Ratliff, T. L. and Nadler, R. B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J.A.M.A., 274: 1214, 1995.
9. Partin, A. W., Catalona, W. J., Southwick, P. C., Subong, E. N., Gasior, G. H. and Chan, D. W.: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology, suppl., 48: 55, 1996.
10. Luderer, A. A., Chen, Y., Soriano, T. F., Kramp, W. J., Carlson, B., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, M. K. and Thiel, R.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology, 46: 187, 1995.
11. Elgamal, A.-A. A., Cornillie, F. J., Van Poppel, H. P., Van de Voorde, W. M., McCabe, R. and Baert, L. V.: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer. J. Urol., 156: 1042, 1996.
12. Van Cangh, P. J., De Nayer, P., Sauvage, P., Tombal, B., Elsen, M., Lorge, F., Opsomer, R. and Wese, F. X.: Free to total prostate-specific antigen (PSA) ratio is superior to total PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate, suppl., 7: 30, 1996.
13. Chen, Y. T., Luderer, A. A., Thiel, R. P., Carlson, G., Cuny, C. L. and Soriano, T. F.: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology, 47: 518, 1996.
14. Woodrum, D. L., Brawer, M. K., Partin, A. W., Catalona, W. J. and Southwick, P. C.: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol., 159: 5, 1997.
15. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N. P., Parson, R. E., Gasior, G. H., Loveland, K. G. and Southwick, P. C.: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J.A.M.A., 279: 1542, 1998.
16. Arcangeli, C. G., Shepherd, D. L., Smith, D. S., Humphrey, P. A., Keetch, D. W. and Catalona, W. J.: Correlation of percent free PSA and pathologic features of prostatic carcinomas. J. Urol., part 2, 155: 415A, abstract 420, 1996.
17. Carter, H. B., Partin, A. W., Luderer, A. A., Metter, E. J., Landis, P., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology, 49: 379, 1997.
18. Arcangeli, C. G., Humphrey, P. A., Smith, D. S., Harmon, T. J., Shepherd, D. L., Keetch, D. W. and Catalona, W. J.: Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology, 51: 558, 1998.
19. Pannek, J., Rittenhouse, H. G., Chan, D. W., Epstein, J. I., Walsh, P. C. and Partin, A. W.: The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol., 159: 1238, 1998.
20. Keetch, D. W., Catalona, W. J. and Smith, D. S.: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J. Urol., 151: 1571, 1994.
21. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
22. Woodrum, D. L., French, C. and Shamel, L. B.: Stability of free P-SA in serum samples under a variety of sample collection and sample storage conditions. Urology, suppl., 48: 33, 1996.
23. Woodrum, D. L. and York, L.: Two-year stability of free and total PSA in frozen serum samples. Urology, 52: 247, 1998.
24. Woodrum, D. L., French, C. M., Hill, T. M., Roman, S. J., Slatore, H. L., Shaffer, J. L., York, L. G., Eure, K. L., Loveland, K. G., Gasior, G. H., Southwick, P. C. and Shamel, L. B.: Analytical performance of the Tandem®-R free PSA immunoassay measuring free prostate specific antigen. Clin. Chem., 43: 1203, 1997.
25. Hosmer, D. W. and Lemeshow, S.: Applied Logistic Regression. New York: John Wiley & Sons, 1989.
26. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
27. Epstein, J. I., Chan, D. W., Sokoll, L. J., Walsh, P. C., Cox, J. L., Rittenhouse, H., Wolfert, R. and Carter, H. B.: Nonpalpable (stage T1c) prostate cancer: Prediction of insignificant disease using free/total (F/T) prostate specific antigen levels and needle biopsy findings. J. Urol., part 2, 159: 2407, 1998.
28. Pannek, J., Subong, E. N., Jones, K. A., Marschke, P. L. S., Epstein, J. I., Chan, D. W., Carter, H. B., Luderer, A. A. and Partin, A. W.: The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology, suppl., 48: 51, 1996.
29. Lerner, S. E., Jacobsen, S. J., Lilja, H., Bergstralh, E. J., Ransom, J., Klee, G. G., Piironen, T., Blute, M. L., Lieber, M. M., Zincke, H., Pettersson, K., Peterson, D. and Oesterling, J. E.: Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology, 48: 240, 1996.
30. Bangma, C. H., Kranse, R., Blijenberg, B. G. and Schröder, F. H.: The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. J. Urol., 157: 544, 1997.
31. Chan, D. W., Sokoll, L. J., Jones, K. A., Kelley, C. A., Subong, E. N. P. and Partin, A. W.: Clinical evaluation of two free PSA assays in combination with different total PSA assays. J. Urol., suppl., 157: 112, abstract 435, 1997.
32. Fortunato, A., Dorizzi, R. M., Marchi, G., Cocco, C. and Davini, A.: fPSA/tPSA ratios obtained using nine commercial assays. Clin. Chem., suppl., 42: 268, 1996.
33. Jung, K., Stephan, C., Lein, M., Henke, W., Schnorr, D., Brux, B., Schurenkamper, P. and Loening, S. A.: Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin. Chem., 42: 1026, 1996.